{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Olix+Pharmaceuticals%2C+Inc.",
    "query": {
      "sponsor": "Olix Pharmaceuticals, Inc."
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 3,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T21:11:49.227Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04877756",
      "title": "Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypertrophic Scar"
      ],
      "interventions": [
        {
          "name": "OLX10010",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Olix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 22,
      "start_date": "2021-08-19",
      "completion_date": "2023-07-12",
      "has_results": false,
      "last_update_posted_date": "2024-02-21",
      "last_synced_at": "2026-10-07T21:11:49.227Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Miami, Florida • Detroit, Michigan + 2 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04877756"
    },
    {
      "nct_id": "NCT05038371",
      "title": "Connective Tissue Growth Factor in Patients With Neovascular Age Related Macular Degeneration",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Wet Macular Degeneration"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2021-09-01",
      "completion_date": "2022-09-22",
      "has_results": false,
      "last_update_posted_date": "2022-09-26",
      "last_synced_at": "2026-10-07T21:11:49.227Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05038371"
    },
    {
      "nct_id": "NCT05643118",
      "title": "Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neovascular Age-related Macular Degeneration"
      ],
      "interventions": [
        {
          "name": "OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA)",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Olix Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2023-01-04",
      "completion_date": "2025-11-10",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-07T21:11:49.227Z",
      "location_count": 5,
      "location_summary": "Santa Maria, California • Oak Forest, Illinois • St Louis, Missouri + 2 more",
      "locations": [
        {
          "city": "Santa Maria",
          "state": "California"
        },
        {
          "city": "Oak Forest",
          "state": "Illinois"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Troy",
          "state": "New York"
        },
        {
          "city": "Bellaire",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05643118"
    }
  ]
}